

**LIST OF REFERENCES CITED BY APPLICANT**

(Use additional sheets if necessary)

ATTY. DOCKET NO.

9516-039-999

APPLICATION NO.

09/704,054

APPLICANT

D'AMATO

FILING DATE

November 1, 2000

ART UNIT

1614

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	2,830,991	04/1958	Keller et al.	
	A02	3,560,495	02/1971	Frankus et al.	
	A03	3,563,986	02/1971	Frankus et al.	
	A04	3,625,946	12/1971	Koch et al.	
	A05	3,705,162	12/1972	Graudums et al.	
	A06	4,552,888	11/1985	Koppel et al.	
	A07	4,808,402	02/1989	Leibovich et al.	
	A08	4,994,443	02/1991	Folkman et al.	
	A09	5,001,116	03/1991	Folkman et al.	
	A10	5,021,404	06/1991	Folkman et al.	
	A11	5,134,127	07/1992	Stella et al.	
	A12	5,260,329	11/1993	Mongelli et al.	
	A13	5,434,170	07/1995	Andrulis, Jr.	
	A14	5,502,066	03/1996	Heinemann et al.	
	A15	5,605,914	02/1997	Muller	
	A16	5,635,517	06/1997	Muller et al.	
	A17	5,643,915	07/1997	Andrulis, Jr. et al.	
	A18	5,654,312	08/1997	Andrulis, Jr. et al.	
	A19	5,679,696	10/1997	Fenton et al.	
	A20	5,731,325	03/1998	Andrulis, Jr. et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	EP 0325199	07/1989			
	B02	EP 0357061	03/1990			
	B03	GB 1182709	03/1970			
	B04	WO 92/14455	09/1992			
	B05	WO 92/18496	10/1992			

NYI-4039463v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9516-039-999	APPLICATION NO. 09/704,054
	APPLICANT D'AMATO	
	FILING DATE November 1, 2000	ART UNIT 1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C23	Schulze-Osthoff, K. et al, Am. J. Pathol. 1990, 137(1), pp. 85-92.	
	C24	Allegri, A., "Confermata l'inefficacia della Talidomide Nella Terapia dei Tumori", Gazzetta Medica Italiana, pp. 124-127 (1964)	
	C25	Aronson, et al., "Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve Cultures", Arch. Dermatol., vol. 120, No. 11, pp. 1466-1470 (1984)	
	C26	Avalos-Diaz, et al., "Inhibitory Effect on Endocytosis in Polymorphonuclear Cells Caused by Thalidomide", Arch. Invest. Med., vol. 16, No. 2, pp. 139-143	
	C27	Bach, et al., "Thalidomide in Cancer Chemotherapy", The Lancet, vol. 1, p. 1271 (1963)	
	C28	Balabanova, et al., "Lupus Erythematosus Hypertrophicus et Profundus", Z. Hautkr., vol. 67, No. 9, pp. 812-815 (1992)	
	C29	Barnhill, et al., "Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various Other Conditions", J. Am. Acad. Dermatol., vol. 7, No. 3, pp. 317-323 (1982)	
	C30	Beccerica, E., "L'approccio terapeutico al paziente anziano con artrite reumatoide", Clin. Ter., vol. 122, pp. 289-298 (1987)	
	C31	Bensinger, W.I., "Supportive Care in Marrow Transplantation", Curr. Opin. Oncol., vol. 4, No. 4, pp. 614-623 (1992)	
	C32	Bonnetblanc, et al., "Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study", Dermatology, vol. 193, No. 4, pp. 321-323 (1996)	
	C33	Boodman, S.G., "Questions About a Popular Prenatal Test", The Washington Post (1992)	
	C34	Bowers, et al., "Effect of Thalidomide on Orogenital Ulceration", Br. Med. Journ., vol. 287, No. 6395, pp. 799-800 (1983)	
	C35	Braun, et al., "Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin a Coated Surfaces", Biochem. Biophys. Res. Comm., vol. 98, No. 4, pp. 1029-1034 (1981)	
	C36	Brodthagen, H., "Significant Response of Oral Aphthosis to Thalidomide Treatment", J. Am. Acad. Dermatol., vol. 13, No. 3, p. 509 (1985)	
	C37	Brovarone, et al., "Occhio e gravidanza", Minerva Ginecol., vol. 43, pp. 141-167 (1991)	
	C38	Bubl, et al., "Dysphagia in Dermatologic Disease", Dysphagia, vol. 8, No. 2, pp. 85-90 (1993)	
	C39	Bullock, W.E., "The Clinical Significance of Erythema Nodosum", Hosp. Pract., vol. 21, No. 3, pp. 102E-2H, 102K-2L, 102Q-2R pas (1986)	
	C40	Burger, et al., "Epidermolysis Bullosa Acquisita, a Rare Late Complication of Allogeneicbone Marrow Transplantation?", Bone Marrow Transplant, vol. 9, No. 2, pp. 139-141 (1992)	
	C41	Calnan, et al., "Actinic Prurigo (Hutchinson's Summer Prurigo)", Clin. Exp. Dermatol., vol. 2, No. 4, pp. 365-372 (1977)	
	C42	Cant, J.S., "Minor Ocular Abnormalities Associated With Thalidomide", The Lancet, p. 1134 (1966)	
	C43	Carmichael, et al., "Thalidomide: A Restricted Role", Lancet, vol. 339, No. 8805, p. 1362 (1992)	
	C44	Chapon, et al., "Neuropathies Caused by Thalidomide", Rev. Neurol., vol. 141, No. 11, pp. 719-728 (1985)	
	C45	Chosidow, O, et al., "Sclerodermatous Chronic Graft-Versus-Host-Disease: Analysis of Sevenscases", J. Am. Acad. Dermatol., vol. 26, No. 1, pp. 49-55 (1992)	
	C46	Claydon, et al., "Gastrointestinal Emergencies in HIV Infection", Balliere's Clin Gastroenterol., vol. 5, No. 4, pp. 887-911 (1991)	
	C47	Clemmensen, et al., "Thalidomide Neurotoxicity", Arch. Dermatol, vol. 120, No. 3, pp. 338-341 (1984)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C48	Congy, et al., "Plasma Zinc Levels in Elderly Patients Hospitalized in Long Stay Units. Correlations with Other Nutritional Markers, Immunological Tests and Survival", Sem. Hop. Paris, vol. 59, No. 45, pp. 3105-3108 (1983)	
	C49	Costa, et al., "Aseptic Adenitis in a Patient with Pyoderma Gangrenosum", Ann. Dermatol., vol. 121, No. 8, pp. 550-552 (1994)	
	C50	Crawford, C.L., "Letter: Thalidomide in Erythema Nodosum Leprosum", Lancet, vol. 2, No. 839, pp. 1201-1202 (1973)	
	C51	Crawford, C.L., "Treatment of Erythema Nodosum Leprosum with Thalidomide", Lancet, vol. 2, No. 828, pp. 567-568 (1973)	
	C52	Crawford, C.L., "Use of Thalidomide in Leprosy [letter; comment]", BMJ, vol. 302, No. 6729, pp. 1603-1604 (1991)	
	C53	Current Bibliographies in Medicine, "Thalidomide: Potential Benefits and Risks", National Inst. Health, National Library of Medicine, pp. 1-72 (Jan. 1963-Jul. 1997)	
	C54	D'Amato, et al., "Angiogenesis Inhibition in Age-Related Macular Degeneration", Ophthalmology, vol. 102, No. 9, pp. 1261-1262 (1995)	
	C55	D'Amato, et al., "Microscopic Analysis of Retinal-Vessels Utilizing Fluorescein-Labeled High-Molecular-Weight Dextrans", Invest. Ophthalmol. & Visual Science, vol. 33, No. 4, p. 1082 (1992)	
	C56	Dark, et al., "Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature", Cancer Research, vol. 37, pp. 1829-1834 (1997)	
	C57	David-Bajar, K.M., "Subacute Cutaneous Lupus Erythematosus", J. Invest. Dermatol. vol. 100, No. 1, pp. 2s-8s (1993)	
	C58	DeKlerk, et al., "New Methods of Treatment for Renal Allotransplants Using the Baboon as a Primate Experimental Model", J. Urol. vol. 102, No. 5, pp. 532-540 (1969)	
	C59	Dhodapkar, et al., "A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients with Multiple Myeloma", UARK 98-003, pp. 1-15	
	C60	DiPaolo, et al., "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro", Science, vol. 144, pp. 1583 (1964)	
	C61	DiPaolo, "Effect of Thalidomide on a Variety of Transplantable Tumors", Cancer Chemo. Reports, vol. 29, pp. 99-102 (1963)	
	C62	DiPaolo, "In Vitro Test Systems for Cancer Chemotherapy. II. Correlation of In Vitro Inhibition of Dehydrogenase and Growth with In Vivo Inhibition of Ehrlich Ascites Tumor", P.S.E.B.M., vol. 114, pp. 384-387 (1963)	
	C63	DiPaolo et al., "Teratogenesis-oncogenesis: A Study of Possible Relationships", Arch. Path., vol. 81, pp. 3-23 (1966)	
	C64	Dorveaux, et al., "Le Traitement Actuel du Lupus Erythemateux Chronique", Le Concours Med. vol. 106, No. 31, pp. 2957-2961 (1984)	
	C65	Doutre, et al., "Pyoderma Gangrenosum and Hemopathies. A propos of 2 Cases", Nouv Rev Fr Hematol, vol. 29, No. 4, pp. 251-254 (1987)	
	C66	Dunn, et al., "Bone Marrow Transplantation and Cataract Development", Arch. Ophthalmol. vol. 111, No. 10, pp. 1367-1373 (1993)	
	C67	(Editorial) "Thalidomide in Dermatology and Leprosy", Lancet, vol. 2, No. 8446, pp. 80-81 (1985)	
	C68	(Editorial) "Thalidomide Tested for Treatment of AIDS", U.S. Pharm., vol. 18, No. 8, p. 14 (1993)	
	C69	Elia, et al., "Giant Esophageal Ulcer Treated with Steroids in AIDS Patient(2)", J. Acquired Immune Defic. Syndr., vol. 5, No. 8, pp. 848-849 (1992)	
	C70	Eriksson, et al., "Drug Exposure and Flow Cytometry Analyses in a Thalidomide Treatment Schedule that Prolongs Rat Cardiac Graft Survival", Transplant Proc., vol. 24, No. 6, pp. 2560-2561 (1992)	
	C71	Fajardo, et al., "Dual Role of Tumor Necrosis Factor- α in Angiogenesis", Am. J. Pathol., vol. 140, No. 3, pp.	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9516-039-999	APPLICATION NO. 09/704,054
	APPLICANT D'AMATO	
	FILING DATE November 1, 2000	ART UNIT 1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		539-544 (1992)	
	C72	Faure, et al., "PMN Leukocytes Chemotaxis: Inhibition by Thalidomide", Pathol. Biol. (Paris), vol. 29, No. 10, pp. 601-604 (1981).	
	C73	Faure, et al., "Inhibition of PMN Leukocytes Chemotaxis by Thalidomide", Arch. Dermatol. Res., vol. 269, No. 3, pp. 275-280 (1980)	
	C74	Francois, J., "Embryological Pigment Epithelial Dystrophies", Ophthalmologica, vol. 172, pp. 417-433 (1976)	
	C75	Fuller, et al., "Thalidomide, Peripheral Neuropathy and AIDS", Int. J. STD AIDS, vol. 2, No. 5, pp. 369-370 (1991)	
	C76	Furner, B.B., "Treatment of Subacute Cutaneous Lupus Erythematosus", Int. J. Dermatol., vol. 29, No. 8, pp. 542-547 (1990)	
	C77	Gad, et al., "Thalidomide Induces Imbalances in T-Lymphocytes Sub-Populations in the Circulating Blood of Healthy Males", Lepr. Rev., vol. 56, No. 1, pp. 35-39 (1985)	
	C78	Gaetani, M., "Studi Sull'Attivita Antitumorale Della Thalidomide", Giornale Italiano di Chemioterapia, pp. 83-86	
	C79	Gehanno, et al., "Mouth and Pharyngeal Hyperalgesic Syndromes in AIDS", Ann. Otolaryngol Chir. Cervicofac, vol. 107, No. 5, pp. 311-313 (1990)	
	C80	Genovo, et al., "Treatment of Aphthosis with Thalidomide and with Colchicine", Dermatologica, vol. 168, No. 4, pp. 182-188 (1984)	
	C81	Geoghiou, et al., "HIV-Associated Oesophageal Ulcers Treated with Thalidomide", Med. J. of Australia, vol. 152, pp. 382-383 (1990)	
	C82	Gershbein, "Effect of Transplanted Tumor and Various Agents on Liver Regeneration During Pregnancy", P.S.E.B.M., vol. 126, pp. 88-92 (1967)	
	C83	Goihman-Yahr, M., et al., "Autoimmune Diseases and Thalidomide II. Adjuvant Disease, Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis of the Rat", Int. J. Leprosy, vol. 42, No. 3, pp. 266-275 (1974)	
	C84	Gorin, I., et al., "Thalidomide May Cure AIDS Ulcers", Nurs. Times, vol. 86, No. 24, p. 10 (1990)	
	C85	Gorin, I., et al., "Thalidomide in Hyperalgesic Pharyngeal Ulceration of AIDS", Lancet, vol. 335, p. 1343 (1990)	
	C86	Goulden, V., et al., "Linear Prurigo Simulating Dermatitis Artefacta in Dominant Dystrophic epidermolysis Bullosa", Br. J. Dermatol., vol. 129, No. 4, pp. 443-446 (1993)	
	C87	Grinspan, et al., "Treatment of Aphthae with Thalidomide", J. Am. Acad. Dermatol., vol. 20, No. 6, pp. 1060-1063 (1989)	
	C88	Grosshans, E., et al., "Thalidomide Therapy for Inflammatory Dermatoses", Int. J. Dermatol., vol. 23, No. 9, pp. 598-602 (1984)	
	C89	Guidetti, E., et al., "Ricerche Sull'azione Immunodepressiva Della Thalidomide e del Prednisolone in Ratti Portatori Di Neoplasie Sperimentalmente Indotte", Cancro, vol. 22, pp. 503-512 (1969)	
	C90	Gunzler, V., "Thalidomide in Human Immunodeficiency Virus (HIV) Patients. A Review of Safety Considerations", Drug Saf., vol. 7, No. 2, pp. 116-134 (1992)	
	C91	Hamza, M.H., "Treatment of Behcet's Disease with Thalidomide", Clinical Rheumatol., vol. 5, No. 3, pp. 365-371 (1986)	
	C92	Harindra, et al., "Papulo-Pruritic Eruption and Giant Ulceration of the Mouth: A Difficult Clinical Feature to Treat in the Patient Infected with Human Immunodeficiency Virus(1)", Arch. Intern. Med., vol. 152, No. 9, p. 1924 (1992)	
	C93	Hasper, M.F., "Chronic Cutaneous Lupus Erythematosus. Thalidomide Treatment of 11 Patients", Arch. Dermatol., vol. 19, No. 10, pp. 812-815 (1983)	
	C94	Hasper, M.F., et al., "Thalidomide in the Treatment of Chronic Discoid Lupus", Acta. Derm. Venereol., vol. 62, No. 4, pp. 321-324 (1982)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C95	Hastings, R.C., et al., "Thalidomide in the Treatment of Erythema Nodosum Leprosum. With a Note on Seleted Laboratory Abnormalities in Erythema Nodosum Leprosum", Clin. Pharmacol. Ther., vol. 11, No. 4, pp. 481-487 (1970)	
	C96	Heaton, et al., "Graft-versus-Host Disease Following Liver Transplantation", J. R. Soc. Med., vol. 85, No. 6, pp. 313-314 (1992)	
	C97	Heney, D., et al., "Thalidomide in the Treatment of Graft-versus-Host Disease", Biomed. Pharmacother, vol. 44, No. 4, pp. 199-204 (1990)	
	C98	Heney, D., et al., "Thalidomide for Chronic Graft-versus-Host Disease in Children", Lancet, vol. 2, No. 8623, p. 1317 (1988)	
	C99	Hojyo, et al., "Actinic Prurigo (9)", Int. J. Dermatol., vol. 31, No. 5, pp. 372-373 (1992)	
	C100	Holm, et al., "Chronic Cutaneous Lupus Erythematosus Treated with Thalidomide", Arch. Dermatol., vol. 129, No. 12, pp. 1548-1550 (1993)	
	C101	Hu, D.E., "Inhibition of Angiogenesis in Rats by IL-1 Receptor Antagonist and Selected Cytokine Antibodies", Inflammation, vol. 18, pp. 45-58 (1994)	
	C102	Ingber, D., "Drug News and Trial Developments", AIDS Patient Care, vol. 6, No. 6, p. 288 (1992)	
	C103	Randall, T., "Thalidomide's Back in the News, but in more Favorable Circumstances", JAMA, vol. 263, No. 11, pp. 1467-1468 (1990)	
	C104	Jacobson, et al., "The Diagnosis and Treatment of Leprosy", South Med. J., vol. 69, No. 8, pp. 979-985 (1976)	
	C105	Jager, et al., "Clinical Observations in the Treatment of Leprosy Reaction with Cyclic Imides", Int. J. Lepr. Other Mycobact Dis., vol. 39, No. 2, p. 589 (1971)	
	C106	Jenkins, et al., "Thalidomide, Orogenital Ulcers, and Risk of Teratogenicity", The Lancet, vol. 1, No. 8417-18, p. 511 (1985)	
	C107	Jenkins, et al., "Thalidomide in Severe Orogenital Ulceration", The Lancet, vol. 2, No. 8417-18, pp. 1424-1426 (1984)	
	C108	Jennings, et al., "Effect of Actinomycin D on the Production of Acute Phase Protein in the Rabbit", Experienta, vol. 25, pp. 305-306 (1969)	
	C109	Jew, et al., "Thalidomide in Erythema Nodosum Leprosum", DICP, vol. 24, No. 5, pp. 482-483 (1990)	
	C110	Jorizzo, et al., "Thalidomide Effects in Behcet's Syndrome and Pustular Vasculitis", Arch. Intern. Med., vol. 146, No. 5, pp. 878-881 (1986)	
	C111	Juret, et al., "Absence d'effet Carcino-Frenateur du Talidomide vis-a-vis de deux Tumeurs Greffees", Societe de Biologie, vol. 23, pp. 246-249 (1963)	
	C112	Kaitin, K.I., "Graft-versus-Host Disease", N. Engl. J. Med., vol. 325, No. 5, pp. 357-358 (1991)	
	C113	Katsuta, et al., "Carcinogenesis in Tissue Culture. 3. Effects of the Second Treatments on DAB-Induced Proliferating Liver Cells of Normal Rats in Culture", Jpn. J. Exp. Med., vol. 35, No. 4, pp. 231-248 (1965)	
	C114	Kenyon, et al., "The Discovery of New Inhibitors of Angiogenesis Using an Improved Mouse Corneal Neovascularization Model", No. 459-367, p. S94 (Abstract only)	
	C115	Knop, et al., "Thalidomide in the Treatment of Sixty Cases of Chronic Discoid Lupus Erythematosus", Br. J. Dermatol, vol. 108, No. 4, pp. 461-466 (1983)	
	C116	Korn, et al., "The Second International Workshop on Scleroderma Research", Matrix, vol. 13, No. 5, pp. 427-429 (1993)	
	C117	Kroger, et al., "Synergistic Effects of Thalidomide and Poly (ADP-ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice", Inflammation, vol. 20, No. 2, pp. 203-215 (1996)	
	C118	Kundu, et al., "Prurigo Nodularis in an HIV Positive Man (2)", Genitourinary Medicine, vol. 71, No. 2, pp. 129-130 (1995)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9516-039-999	APPLICATION NO. 09/704,054
	APPLICANT D'AMATO	
	FILING DATE November 1, 2000	ART UNIT 1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C119	Lane, et al., "Treatment of Actinic Prurigo with Intermittent Short-Course Topical 0.05% Clobetasol 17-Propionate. A Preliminary Report", Arch. Dermatol, vol. 126, No. 9, pp. 1211-1213 (1990)	
	C120	Languillon, J., "The Effects of Thalidomide on Leprosy Reaction", Int. J. Lepr. Other Mycobact. Dis., vol. 39, No. 2, pp. 590-592 (1971)	
	C121	Ledo, E., "Photodermatosis. Part I: Photobiology, Photoimmunology, and Idiopathic photodermatoses", Int. J. Dermatol., vol. 32, No. 6, pp. 387-396 (1993)	
	C122	Lehner, T., et al., "Thalidomide, Orogenital Ulcers, and the Risk of Teratogenesis", The Lancet, vol. 8423, pp. 288-289 (1985)	
	C123	Levy, et al., "Treatment of Erythema Nodosum Leprosum with Thalidomide", The Lancet, vol. 2, No. 824, pp. 324-325 (1973)	
	C124	Lenicque, "Action of Thalidomide on the Induction of Tentacles in Regenerating Hydra Littoralis", Acta. Zool., pp. 127-139 (1967)	
	C125	Lo, et al., "Treatment of Discoid Lupus Erythematosus", Int. J. Dermatol., vol. 28, No. 8, pp. 497-507 (1989)	
	C126	Londono, F., "Thalidomide in the Treatment of Actinic Prurigo", Int. J. Dermatol., vol. 12, No. 5, pp. 326-328 (1973)	
	C127	Lovell, et al., "Thalidomide in Actinic Prurigo", Br. J. Dermatol, vol. 108, No. 4, pp. 467-471 (1983)	
	C128	Magana-Garcia, M., "Antimalarials for Children", J. Am. Acad. Dermatol, vol. 30, No. 3, p. 510 (1994)	
	C129	Mascaro, et al., "Thalidomide in the Treatment of Recurrent, Necrotic, and Giant Mucocutaneous Aphthae and Aphthosis", Arch. Derm., vol. 115, pp. 636-637 (1979)	
	C130	Matsubara, et al., "Inhibition of Human Endothelial Cell Proliferation by Gold Compounds", J. Clin. Invest., vol. 79, pp. 1440-1446 (1987)	
	C131	Mauad, "Melhoras Clinicas Obtidas em Doentes Cancerosos Avan. cedilla. ados com Tratamento Pela Talidomida Associada a Hormonios", Anais Paulistas Medicina e Cirurgia, pp. 15-39 (1963)	
	C132	Maurice, et al., "The Effect of Thalidomide on Arachidonic Acid Metabolism in Human Polymorphonuclear Leukocytes and Platelets", Br. J. Dermatol., vol. 115, No. 6, pp. 677-680 (1986)	
	C133	McCarthy, et al., "Thalidomide for the Therapy of Graft-versus-Host Disease Following Allogeneic Bone Marrow Transplantation", Biomed. Pharmacother., vol. 43, No. 9, pp. 693-697 (1989)	
	C134	McKenna, et al., "Linear IgA Disease, Oral Ulceration and Crohn's Disease", Br. J. Dermatol, vol. 127, pp. 67-68 (1992)	
	C135	Miller, et al., "Zusammentreffen Einer Thalidomid-Induzierten Fehlbildung mit Einem Malignen Lymphom Hohen Malignitatsgrades", Monatsschr. Kinderheilkd., vol. 128, pp. 27-29 (1980)	
	C136	Miller, et al., "Treatment of Chronic Erythema Nodosum Leprosum with Cyclosporine A Produces Clinical and Immunohistologic Remission", Int. J. Lepr. Other Mycobact. Dis., vol. 55, No. 3, pp. 441-449 (1987)	
	C137	Miyachi, Y., "A Possible Mechanism of Action of Thalidomide on Rheumatoid Arthritis", Arthritis and Rheuma., vol. 28, No. 7, p. 836 (1985)	
	C138	Miyachi, et al., "Effects of Thalidomide on the Generation of Oxygen Intermediates by Zymosan-Stimulated Normal Polymorphonuclear Leukocytes", Arch. Dermatol. Res., vol. 274, Nos. 3-4, pp. 363-367 (1982)	
	C139	Mohri, et al., "Negative Effect of Thalidomide and Relative Substances on the Growth of HeLa Cells", Chem. Pharm. Bull., vol. 16, pp. 2289-2292 (1968)	
	C140	Moncada, et al., "Thalidomide--Effect on T Cell Subsets as a Possible Mechanism of Action", Int. J. Lepr. Other Mycobact. Dis., vol. 53, No. 2, pp. 201-205 (1985)	
	C141	Montrucchio, et al., "Tumor Necrosis Factor .alpha.-Induced Angiogenesis Depends on In Situ Platelet-Activating Factor Biosynthesis", J. Exp. Med., vol. 180, pp. 377-382 (1994)	
	C142	Mshana, et al., "Thymus-Dependent Lymphocytes in Leprosy. II. Effect of Chemotherapy on T-Lymphocyte Subpopulations", J. Clin. Immunol., vol. 2, No. 2, pp. 69-74 (1982)	

NYI-4039463v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C143	Muckter, et al., "Thalidomide and Tumor", Antimicrobial Agents and Chemotherapy, pp. 531-538 (1965)	
	C144	Munro, et al., "Pyoderma Gangrenosum Associated with Behcet's Syndrome-Response to Thalidomide", Clin. Exp. Dermatol., vol. 13, No. 6, pp. 408-410 (1988)	
	C145	Moulin, et al., "Treatment of Jessner-Kanof Disease with Thalidomide", Ann. Dermatol Venereol, vol. 10, No. 8, pp. 611-614 (1983)	
	C146	Naafs, B., Bangkok Workshop on Leprosy Research. Treatment of Reactions and Nerve Damage. Int. J. Lepr. Other Mycobact. Dis., vol. 64, No. 4, Suppl. S21-28 (1996)	
	C147	Neubert, "Teratogenicity: Any Relationship to Carcinogenicity?", Institute for Toxicology and Embryopharmacology, Free University of Berlin, Berlin, Federal Rep. Of Germany, pp. 169-178	
	C148	Nicolas, J., et al., "Interferon Alfa Therapy in Severe Unresponsive Subacute Cutaneous Lupus Erythematosus", New Engl. J. Med., vol. 321, No. 22, pp. 1550-1551 (1989)	
	C149	Nicolau, et al., "Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS", DICP, vol. 24, No. 11, pp. 1054-1056 (1990)	
	C150	Nielsen, et al., "Thalidomide Enhances Superoxide Anion Release from Human Polymorphonuclear and Leukocytes", Acta. Pathol. Microbiol. Immunol. Scand. [C], vol. 94, No. 6, pp. 233-237 (1986)	
	C151	Olson, et al., "Thalidomide (N-phthaloylglutamide) in the Treatment of Advanced Cancer", Clin. Pharmacol. Therap., vol. 6, No. 3, pp. 292-297 (1965)	
	C152	Orzalesi, M., "Il Danno Iatrogeno in Neonatologica", Ped. Med. Chir., vol. 14, pp. 105-112 (1992)	
	C153	Ostraat, et al., "Thalidomide Prolongs Graft Survival in Rat Cardiac Transplants", Transplant Proc., vol. 24, No. 6, pp. 2624-2625 (1992)	
	C154	Paller, et al., "Proceedings of the Concurrent Sessions", Pediatr. Dermatol, vol. 9, No. 4, pp. 397-406 (1992)	
	C155	Pearson, et al., "Treatment of Moderately Severe Erythema Nodosum Leprosum with Thalidomide--A Double-Blind Controlled Trial", Lepr. Rev., vol. 40, No. 2, pp. 111-116 (1969)	
	C156	Peyron, et al., "The Pharmacological Basis for the Treatment of Photodermatoses", Biochimie, vol. 68, No. 6, pp. 899-904	
	C157	Pfordte, "Über die Beeinflussung des Serumproperdinsystems Durch Verschiedene Arzneimittel", Pharmazie, vol. 26, pp. 301-302 (1971)	
	C158	Phillips, et al., "Tumor Necrosis Factor Alpha (rhTNF) Fails to Stimulate Angiogenesis in the Rabbit Cornea", Anatomical Rec., vol. 245, pp. 53-56 (1996)	
	C159	Proenca, N.G., "Thalidomide: An Eclectic Medication in Dermatology", Rev. Paul. Med., vol. 107, No. 1, pp. 41-46	
	C160	Radeff, et al., "Recurrent Aphthous Ulcer in Patient Infected with Human Immunodeficiency Virus: Successful Treatment with Thalidomide", J. Am. Acad. Dermatol, vol. 23, No. 3, Pt. 1, pp. 523-525 (1990)	
	C161	Rajan, et al., "A Clinical Study of Thalidomide Comparing Pre-Treatment and Post-Treatment Reactional Episodes and Corticosteroid Requirements", Lepr. India, vol. 55, No. 1, 111-116 (1983)	
	C162	Randall, T., "Investigational New Drug (US) 'Orphan' Trials now Use Thalidomide from two Sources", JAMA, vol. 263, No. 11, p. 1474 (1990)	
	C163	Roe, et al., "Tumour-Incidence in Progeny of Thalidomide-Treated Mice", British J. Cancer, pp. 331-333, (1965)	
	C164	Ruggenini, et al., "Taliidomide e Tumori Sperimentali", Cancro, vol. 20, pp. 39-55 (1967)	
	C165	Rustin, et al., "Pyoderma Gangrenosum Associated with Behcet's Disease: Treatment with Thalidomide", J. Am. Acad. Dermatol, vol. 23, No. 5, Pt. 1, pp. 941-944 (1990)	
	C166	Ryan, et al., "Thalidomide to Treat Esophageal Ulcer in AIDS (6)", New Engl. J. Med., vol. 327, No. 3, pp. 208-209 (1992)	
	C167	Sampaio, et al., "Prolonged Treatment with Recombinant Interferon Gamma Induces Erythema Nodosum	

NYI-4039463v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Lepromatous Leprosy Patients", J. Exp. Med., vol. 175, No. 6, pp. 1729-1737 (1992)	
	C168	Sampaio, et al., "Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes", J. Exp. Med., vol. 173, No. 3, pp. 699-703 (1991)	
	C169	Santis, H.R., "Apthous Stomatitis and its Management", Curr. Opin. Dent, vol. 1, No. 6, pp. 763-768 (1991)	
	C170	Santos, et al., "In Vitro Tumor Necrosis Factor Production by Mononuclear Cells from Lepromatous Leprosy Patients and from Patients with Erythema Nodosumleprosum", Clin. Immunol. Immunopathol., vol. 67, No. 3 1, pp. 199-203 (1993)	
	C171	Shannon, et al., "Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy", Scand. J. Immunol., vol. 13, No. 6, pp. 553-562 (1981)	
	C172	Shannon, et al., "Thalidomide's Effectiveness in Erythema Nodosum Leprosum is Associated with a Decrease in CD4+ Cells in the Peripheral Blood", Lepr. Rev., vol. 63, No. 1, pp. 5-11 (1992)	
	C173	Sheehan, N.J., "Thalidomide Neurotoxicity and Rheumatoid Arthritis", Arthritis and Rheuma., vol. 29, No. 10, p. 1296 (1986)	
	C174	Sheskin, J., "The Treatment of Lepra Reaction in Lepromatous Leprosy. Fifteen Years' Experience with Thalidomide", Int. J. Dermatol., vol. 19, No. 6, pp. 318-322 (1980)	
	C175	Sheskin, et al., "In Vivo Measurements of Iron, Copper and Zinc in the Skin of Prurigo Nodularis Patients Treated with Thalidomide", Dermatologica, vol. 162, No. 2, pp. 86-90 (1981)	
	C176	Silverman, W.A., "Medical Inflation", Persp. Biol. Med., pp. 617-637 (1980)	
	C177	Smith, et al., "Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds", Chemical Structure and Embryopathy, pp. 194-209	
	C178	Style, A., "Early Diagnosis and Treatment of Leprosy in the United States", American Family Physician, vol. 52, No. 1, 172-178 (1995)	
	C179	Sugiura, et al., "Effect of Thalidomide on Transplantable Mouse, Rat, and Hamster Tumors", GANN, vol. 55, pp. 57-60 (1964)	
	C180	Suzuki, H., "The History of Iatrogenic Diseases in Japan", First Department of Internal Medicine, University of Envir. And Occup. Health, Kitakyushu, Japan, pp. 35-40	
	C181	Swift, T.R., "Thalidomide in Erythema Nodosum Leprosum", Lancet, vol. 2, No. 835, p. 966 (1973)	
	C182	Szydlowska, et al., "On the Application of Thalidomide as a Block of Functional Groups of Proteins in Histochemical Investigations", Folia Histo. Cytochem., vol. 16, No. 3, pp. 233-240 (1978)	
	C183	Tamura, et al., "Combination Thalidomide and Cyclosporine for Cardiac Allograft Rejection. Comparison with Combination Methylprednisolone and Cyclosporine", Transplantation, vol. 49, No. 1, p. 20-25 (1990)	
	C184	Theophilus, S., "Treatment with Thalidomide in Steroid Dependency and Neuritis", Lepr. India, vol. 52, No. 3, pp. 423-428 (1980)	
	C185	Thomas, et al., "Effect of Thalidomide on Liver Regeneration in Rat", Indian J. Exp. Biol., vol. 10, pp. 314-315 (1972)	
	C186	Thomas, et al., "Lack of Thalidomide Induced Aplasia in Regenerating Tail of Lizard, Hemidactylus Flaviviridis", Indian J. Exp. Biol., vol. 10, pp. 316-317 (1972)	
	C187	Traldi, et al., "L'impiego Dell'imide Dell'Acido N'falilglutammico (Talidomide) Nella Terapia Sintomatica del Vomito di Molti Pazienti Affetti da Neoplasie Maligne o Causato Dalla Somministrazione di Cloridato di Mecloretamina", Cancro, vol. 18, No. 1, pp. 336-341 (1965)	
	C188	Trautman, J. R., "Treatment of Hansen's Disease", Cutis, vol. 18, No. 1, 62-65 (1976)	
	C189	Van den Broek, H., "Treatment of Prurigo Nodularis with Thalidomide", Arch. Dermatol, vol. 116, No. 5, pp. 571-572 (1980)	
	C190	Vasilescu, et al., "Cercetari Privind Actiunea Talidomidei Asupra Celulelor Cultivate in Vitro", Cerc. Fiziol., vol. 13, No. 4, pp. 293-300 (1968)	

NYI-4039463v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C191	Villa, et al., "Antimytotic Effect of Thalidomide and its Metabolites on the Chick Embryo Blood Cells", Haematol. Latina, vol. 6, pp. 217-221 (1963)	
	C192	Villa, et al., "Cytological Effects of Thalidomide", The Lancet, pp. 725 (1963)	
	C193	Vogelsang, et al., "Therapy of Chronic Graft-v-Host Disease in a Rat Model", Blood, vol. 74, No. 1, No. 1, pp. 507-511 (1989)	
	C194	Vogelsang, et al., "Thalidomide Induction of Bone Marrow Transplantation Tolerance", Transplant Proc., vol. 19, No. 1, Pt. 3, pp. 2658-2661 (1987)	
	C195	Vogelsang, et al., "Treatment and Prevention of Acute Graft-versus-Host Disease with Thalidomide in a Rat Model", Transplantation, vol. 41, No. 5, pp. 644-647 (1986)	
	C196	Waters, M., "Use of Thalidomide in Leprosy", BMJ, vol. 303, No. 6800, p. 470 (1991)	
	C197	Waters, M.F., "An Internally-Controlled Double Blind Trial of Thalidomide in Severe Erythema Nodosum Leprosum", Lepro. Rev., vol. 42, No. 1, pp. 26-42 (1971)	
	C198	Wesolowski, et al., "Effect of Light on a Murine Model of Retinopathy of Prematurity", Invest. Opthamol. & Visual Science, vol. 33, No. 4, p. 1281 (Abstract only)	
	C199	Williams, et al., "Thalidomide Hypersensitivity in AIDS", Lancet, vol. 337, pp. 436-437 (1991)	
	C200	Winkelmann, et al., "Thalidomide Treatment of Prurigo Nodularis", Acta. Derm. Venereol., vol. 64, No. 5, pp. 412-417 (1984)	
	C201	Wood, et al., "The Potential use of Thalidomide in the Therapy of Graft-versus-Host Disease--A Review of Clinical and Laboratory Information", Leuk. Res., vol. 14, No. 5, pp. 395-399 (1990)	
	C202	Woodyatt, P.B., "Thalidomide", The Lancet, p. 750. (1962)	
	C203	Wulff, et al., "Development of Polyneuropathy During Thalidomide Therapy", Br. J. Dermatol., vol. 112, No. 4, pp. 475-480 (1985)	
	C204	Yazici, et al., "Practical Treatment Recommendations for Pharmacotherapy of Behcet's Syndrome", Drugs, vol. 42, No. 5, pp. 796-804 (1991)	
	C205	Youle, et al., "Treatment of Resistant Aphthous Ulceration with Thalidomide in Patients Positive for HIV Antibody", BMJ, vol. 298, No. 6671, p. 432 (1989)	
	C206	Youle, et al., "Thalidomide in Hyperalgic Pharyngeal Ulceration of AIDS", Lancet, vol. 335, No. 8705, p. 1591 (1990)	
	C207	Young, et al., "Thalidomide Therapy on a Case of Prurigo Nodularis", Ann. Dermatol., vol. 5, No. 2, pp. 117-120 (1993)	
	C208	Fazal, N. et al., "Effect of blocking TNF-.alpha. on intracellular BCG (Bacillus Calmette Guerin) growth in human monocyte-derived macrophages", FEMS Microbiology Immunology, vol. 105, pp. 337-346 (1992)	
	C209	Louzir, B. et al., "Erythroleucemie chez un patient ayant une maladie de Behcet et traite au long cours par thalidomide", Annales De Medecine Interne, vol. 143, pp. 479-480, (1992)	
	C210	Hatfill, S.J., et al., "Induction of Morphological Differentiation in the Human Leukemic Cell Line K562 by Exposure to Thalidomide Metabolites", Leukemia Research, vol. 15, No. 2/3, pp. 129-136 (1991)	
	C211	"Thalidomide: 20 Years On", The Lancet, vol. II, No. 8245, pp. 510-511 (1981)	
	C212	Revuz, J., "Actualite du Thalidomide", Annales De Dermatologie, vol. 117, pp. 313-321 (1990)	
	C213	Vladutiu, A., "Another Chance for Thalidomide?", The Lancet, vol. I, No. 7444, pp. 981-982 (1966)	
	C214	Fabro, S. et al., "The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its Metabolites", British Journal of Pharmacology and Chemotherapy, vol. 25, pp. 352-362 (1965)	
	C215	Fabro, S., "Biochemical Basis of Thalidomide Teratogenicity", The Biochemical Basis of Chemical Teratogenesis, Chapter 5, pp. 159-178 (1981)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9516-039-999	APPLICATION NO. 09/704,054
	APPLICANT D'AMATO	
	FILING DATE November 1, 2000	ART UNIT 1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C216	Eisenbud, L. et al., "Recurrent aphthous stomatitis of the Behcet's type: Successful treatment with thalidomide", Oral Surgery, Oral Medicine, Oral Pathology, vol. 64, No. 3, pp. 289-292 (1987)	
	C217	Buckley, C. et al., "Pyoderma Gargrenosum with Severe Pharyngeal Ulceration", Journal of the Royal Society of Medicine, vol. 83, pp. 290-291 (1990)	
	C218	Barnes, P.F. et al., "Tumor Necrosis Factor Production in Patients with Leprosy", Infection and Immunity, vol. 60, No. 4, pp. 1441-1446 (1992)	
	C219	Barnhill, R.L. et al., "Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes", Journal of the American Academy of Dermatology, vol. 11, No. 5, Part 1, pp. 814-819 (1984)	
	C220	Dicken, C.H., "Malignant Pyoderma", Journal of the American Academy of Dermatology, vol. 13, No. 6, pp. 1021-1025 (1985)	
	C221	O'Patey, et al., "Thalidomide et colite ulcereuse dans la maladie de Behcet", Gastroenterol Clinique Biologique, vol. 13, pp. 104-110 (1989)	
	C222	Naafs, B. et al., "Thalidomide Therapy", International Journal of Dermatology, vol. 24, No. 2, pp. 131-134 (1985)	
	C223	Blaschke, V.G. et al., "Chromatographische Racemattrennung von Thalidomide und teratogene Wirkung der Enantiomere", Arzneimittel Forschung Drug Research, vol. 11, No. 10, 1640-1642 (1979)	
	C224	Kaplan, G. et al., "TNF.alpha. regulation of HIV1: biology and therapy", Research in Immunology, vol. 145, No. 8-9, pp. 685-690 (1994)	
	C225	Bazzoli, A.S. et al., "The effects of thalidomide and two analogues on the regenerating forelimb of the newt", Journal of Embryology and Experimental Morphology, vol. 41, pp. 125-135 (1977)	
	C226	Bernal, J.E. et al., "Cellular Immune Effects of Thalidomide in Actinic Prurigo", International Journal of Dermatology, vol. 31, No. 8, pp. 599-600 (1992)	
	C227	Chaudhry, A. P. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamsters", Cancer Research, vol. 26, Part 1, pp. 1884-1886 (1996)	
	C228	Gershbein, L. L., "The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas", Cancer Letters, vol. 60, pp. 129-133 (1991)	
	C229	Rainsford, K.D., "Disease-modifying antirheumatic and immunoregulatory agents", Bailliere's Clinical Rheumatology International Practice and Research, vol. 4, No. 3, pp. 405-433 (1990)	
	C230	Hamza, M., "Behcet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide", Clinical and Experimental Rheumatology, vol. 8, No. 4, pp. 427 (1990)	
	C231	Ehrlich, G.E., "Behcet's Disease: Current Concepts", Comprehensive Therapy, vol. 15, No. 1, pp. 27-30 (1989)	
	C232	Barriere, H., "Sarcoides Cutanees. Traitement par la thalidomide", La Presse Medicale, vol. 15, No. 12, pp. 963 (1983)	
	C233	Haffner, M.E., "Studies Involving Orphan Products for Treating/Diagnosing Women's Diseases", Food and Drug Law Journal, vol. 48, pp. 205-211 (1993)	
	C234	Sherman, et al., "Thalidomide: A Twenty-Five Year Perspective", Food Drug Cosmetic Law Journal, vol. 41, pp. 458-466 (1986)	
	C235	Burrows, N. P., "Diagnosis and Management of Systemic Lupus Erythematosus Thalidomide Modifies Disease", British Medical Journal, vol. 307, No. 6909, pp. 939-940 (Oct. 1993)	
	C236	Gutierrez-Rodriguez, O. "Thalidomide A Promising New Treatment for Rheumatoid Arthritis", Arthritis and Rheumatism, vol. 27, No. 10, pp. 1118-1121 (Oct. 1984)	
	C237	Gutierrez-Rodriguez, O., et al., "Treatment of Refractory Rheumatoid Arthritis--The Thalidomide Experience", Journal of Rheumatology, vol. 16, No. 2, pp. 1158-1163 (Feb. 1989)	
	C238	Williams, K.M., "Enantiomers in Arthritic Disorders", Pharmacology & Therapeutics, vol. 46, No. 2, pp. 273-295 (1990)	
	C239	De Cock, K. M., "Treatment of Ulcerative Colitis", letter, British Medical Journal, vol. 1, p. 1356 (May 1979)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C240	Larsson, H., Treatment of Severe Colitis in Behcet's Syndrome with Thalidomide (CG-217), Journal of Internal Medicine, vol. 228, No. 4, pp. 405-407 (Oct. 1990) [letter]	
	C241	Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", Journal of Autoimmunity, vol. 2, pp. 197-202 (1989)	
	C242	Gunzler, V. "Thalidomide--A Therapy for the immunological Consequences of HIV Infection?", vol. 30, No. 2, pp. 105-109 (Oct. 1989)	
	C243	Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatology, vol. 10, No. 3, pp. 256-258 (Sep. 1993)	
	C244	Handley, J. et al., "Chronic Bullous Disease of Childhood and Ulcerative Colitis", Pediatric Dermatology, vol. 127, Supplement 40, pp. 67-68 (Jul. 1992)	
	C245	Field, E.O. et al., "Effect of Thalidomide on the Graft Versus Host Reaction", Nature A Weekly Journal of Science, vol. 211, No. 5055, p. 1308-1310 (Sep. 1966)	
	C246	Hellmann, K. et al., "Prolongation of Skin Homograft Survival by Thalidomide", British Medical Journal, vol. II, pp. 687-689 (Sep. 1965)	
	C247	Heney, D. et al., "Thalidomide Treatment for Chronic Graft-Versus-Host Disease", British Journal of Haematology, vol. 78, pp. 23-27 (1991)	
	C248	Keenan, R. J. et al., "Immunosuppressive Properties of Thalidomide Inhibition on In Vitro Lymphocyte Proliferation Alone and in Combination with Cyclosporine or FK506", Transplantation, vol. 52, No. 5, pp. 908-910 (Nov. 1991)	
	C249	Lopez, J. et al., "Thalidomide as Therapy for Intestinal Chronic GVHD", Bone Marrow Transplantation, vol. 11, No. 3, pp. 251-252 (1993)	
	C250	Bach, A. et al., "Studies on the Possible Anti-Neoplastic Effect of Thalidomide", ACTA Pathologica et Microbiologica Scandinavica, vol. 59, pp. 491-499 (1963)	
	C251	Bahmer, F. A., Therapy of Lymphocytic Infiltration, Der Hautarzt, vol. 43, p. 663 (1992)	
	C252	Gershbein L. L., "Effect of Various Agents on Liver Regeneration and Walker Tumor Growth in Partially Hepatectomized Rats", Cancer Research, vol. 26 Part 1, pp. 1905-1908 (Sep. 1966)	
	C253	Roe, F. J. et al., "Thalidomide and Neoplasia", Nature, vol. 200, pp. 1016-1017 (Dec. 1963). Makonkawkeyoon, S. et al., "Thalidomide Inhibits the Replication of Human Immunodeficiency Virus Type 1", Proceedings of the National Academy of Sciences, vol. 90, No. 13, pp. 5974-5978 (Jul. 1993)	
	C254	Meza, A.D. et al., "Managing the Gastrointestinal Complications of AIDS", Drug Therapy, vol. 23, No. 11, pp. 74-83 (1993)	
	C255	Ghigliotti, G. R. et al., "Thalidomide: Treatment of Choice of Aphthous Ulcers in Patients Seropositive for Human Immunodeficiency Virus", Journal of the American Academy of Dermatology, vol. 28, No. 2, Part 1, pp. 271-272 (Feb. 1993)	
	C256	Grinspan, D., "Significant Response of Oral Aphthosis to Thalidomide Treatment", American Academy of Dermatology, vol. 12, No. 1, Part 1, pp. 85-90 (Jan. 1985)	
	C257	Kurkcuglu, N. et al., "Thalidomide in the Treatment of Recurrent Necrotic Mucocutaneous Aphthae", British Journal of Dermatology, vol. 112, No. 5, p. 632 (May 1985)	
	C258	Powell, R.J. et al., "Investigation and Treatment of Orogenital Ulceration; Studies on a Possible Mode of Action of Thalidomide", British Journal of Dermatology, vol. 113, Supplement 28, pp. 141-144 (1985)	
	C259	Revuz, J. et al., "Crossover Study of Thalidomide vs. Placebo in Severe Recurrent Aphthous Stomatitis", Archives of Dermatology, vol. 126, No. 7, pp. 923-927 (Jul. 1990)	
	C260	Apt, W., "Effect of Thalidomide on the Course of Experimental Chagas' Disease", BOI Chili Parasitol, vol. 20, No. 3, pp. 84-86 (Sep. 1965)	
	C261	Vicente, T. et al., "In Vitro Activity of Thalidomide against mycobacterium Avium Complex", Archives of Internal Medicine, vol. 153, p. 534 (Feb. 1993)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C262	Eravelly, J. et al., "Thalidomide in Weber-Christian Disease", Lancet, vol. 1, No. 8005, p. 251 (1977) [letter]	
	C263	Lueprasitakul, W. et al., "Effect of Thalidomide on the incidence of Iodine-Induced and Spontaneous Lymphocytic Thyroiditis and Spontaneous Diabetes Mellitus in the BB/W or Rat", Acta Endocrinologica, vol. 123, No. 1, pp. 79-83 (Jul. 1990)	
	C264	Misery, L. et al., "Remission of Langerhans Cell Histiocytosis with Thalidomide Treatment", Clinical and Experimental Dermatology, vol. 18, No. 5, p. 487 (Sep. 1993)	
	C265	Rhoton, A.J., "Rle for Thalidomide in Primary Biliary Cirrhosis Treatment", Gastroenterology, vol. 105, No. 3, p. 956 (Sep. 1993)	
	C266	Thomas, L. et al., "Successful treatment of Adult's Langerhans Cell Histiocytosis with Thalidomide, Report of Two cases and Literature Review", Archives of Dermatology, vol. 129, pp. 1261-1264 (Oct. 1993)	
	C267	Prigent F. et al., "Cutaneous Saarcoidosis. Treatment with Thalidomide", Press Med., vol. 12, No. 47, p. 3007 (1983) [French]	
	C268	Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds," Life Sciences, 3:987-992 (1964)	
	C269	Shealy et al., "D- and L-Thalidomide," Chem. and Indus., pp. 1030-1031 (Jun. 12, 1965)	
	C270	Folkman, "Tumor Angiogenesis: Therapeutic Implications," The New England Journal of Medicine, 285(21):1182-1186 (Nov. 18, 1971)	
	C271	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," Acta Pharm. Succica, 9:521-542 (1972)	
	C272	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," Acta Pharm. Succica, 9:431-446 (1972)	
	C273	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," Acta Pharm. Succica, 9:543-562 (1972)	
	C274	Eriksson, Sven O., "Synthesis and Alkaline Hydrolysis of some N-substituted Phthalimides," Acta Pharm. Succica, 10:63-74 (1973)	
	C275	Gimbrone et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea," J. Nat'l Cancer Institute, 52(2):413-419 (1974)	
	C276	Fickentscher, K., "Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides," Mol. Pharmacology, 13:133-141 (1977)	
	C277	Knighton et al., "Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo," Br. J. Cancer, 35:347-356 (1977)	
	C278	Blaschke, "Chromatographic Separation of Racemic Thalidomide and Teratogenic Activity of its Enantiomers (Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere)," Drug Research, 29 (II/10): 1640-1642 (1979). (English lang. summary on first page)	
	C279	Muthukkaruppan et al., "Angiogenesis in the Mouse Cornea," Science, 205:1416-1418 (Sep. 28, 1979)	
	C280	Waters, et al., "Treatment of Ulcerative Colitis with Thalidomide," British Medical Journal, p. 792 (Mar. 24, 1979)	
	C281	Flohe et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis," Arzneimittelforschung (Germany, West), 31(2):315-20 (1981)	
	C282	Helm, Drug Research, 31 (1/6): 941-949 (1981)	
	C283	Taylor et al., Nature, 297: p. 307 (1982)	
	C284	Belaube et al., "Should Thalidomide be Rehabilitated?," Sem. Hop. Paris, 59(45):3101-3104 (Dec. 8, 1983)	
	C285	Folkman et al., Science, 221: p. 719 (1983)	
	C286	Hendler, Sheldon S. et al., "Thalidomide for Autoimmune Disease," Medical Hypotheses, 10:437-443 (1983)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9516-039-999	09/704,054
	APPLICANT	
	D'AMATO	
	FILING DATE	ART UNIT
	November 1, 2000	1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C287	Crum et al., Science, 230: 1375 et seq. (1985)	
	C288	Koch, H.P. et al., "Thalidomide and Cogeners as Anti-inflammatory Agents," Progress in Medicinal Chemistry, 22:166-242 (1985)	
	C289	Sidky et al., Cancer Research, 47: pp 5155-5161 (1987)	
	C290	Srivastava et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin Melanoma," Am. J. Pathol., 133:419-423 (1988). (abstract from Medline: Accession No. 06745734)	
	C291	Chen et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide After Oral Dosing in Healthy Male Volunteers," Drug Metabolism and Disposition, 17(4):402-405 (1989)	
	C292	White et al., New England J. Med., 320: pp. 1197-1200 (1989)	
	C293	Folkman et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," Nature, 339:58-61 (May 4, 1989)	
	C294	"Thalidomide," The Merck Index, Eleventh Edition, Budavari et al., eds., Merck & Co., New Jersey, p. 9182 (1989)	
	C295	Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide," Arzneim.-Forsch/Drug Res. 40 (II. Nr. 10):1073-1075 (1990)	
	C296	Ingber et al., "Synthetic Analogs Of Fumagillin That Inhibit Angiogenesis And Suppress Tumour Growth," Nature, 348:555-557 (Dec. 6, 1990)	
	C297	Brem et al., Neurosurg., 74: 441-446 (1991)	
	C298	Matsuyama, Toshifumi, "Cytokines and HIV infection: is AIDS a Tumor Necrosis Factor Disease?," AIDS, 5(12):1405-1417 (1991)	
	C299	Weidner et al., "Tumor Angiogenesis and Metastasis--Correlation in Invasive Breast Carcinoma," N.E. J. Med., 324(1):1-8 (1991)	
	C300	Colville-Nash et al., "Angiogenesis and Rheumatoid Arthritis: Pathogenic and Therapeutic Implications," Ann. Rheum. Dis., 51:919-925 (1992)	
	C301	Folkman and Shing, "Angiogenesis," J. Biol. Chem., 267(16):10931-10934 (1992)	
	C302	Schweigerer and Fotsis, "Angiogenesis and angiogenesis inhibitors in paediatric diseases," Eur. J. Pediatr. 151:472-476 (1992)	
	C303	Torrey and Rongish, "Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis," Am. J. Reprod. Immunol., 27:171-179 (1992)	
	C304	Vogelsang et al., "Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease," New England Journal of Medicine, 326:1055-1058 (1992)	
	C305	Weidner et al., "Angiogenesis in Prostate Carcinoma," Am. J. Path., 143(2):401-409 (1993)	
	C306	D'Amato et al., "Thalidomide is an Inhibitor of Angiogenesis," PNAS USA, 91:4082-4085 (1994)	
	C307	Oikawa et al., "Eponemycin, A Novel Antibiotic, is a Highly Powerful Angiogenesis Inhibitor," Biochem. Biophys. Res. Comm., 181(3):1070-1076 (Dec. 31, 1991)	
	C308	Otsuka et al., "A New Potent Angiogenesis Inhibitor, FR-118487," J. Microb. Biotech., 1(3):163-168 (1991)	

NYI-4039463v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	